請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61798
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳進庭(Chin-Tin Chen) | |
dc.contributor.author | Wei-Ting Ou | en |
dc.contributor.author | 歐瑋婷 | zh_TW |
dc.date.accessioned | 2021-06-16T13:13:37Z | - |
dc.date.available | 2015-08-09 | |
dc.date.copyright | 2013-08-09 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-07-30 | |
dc.identifier.citation | 1. Attardi, G. and G. Schatz, Biogenesis of mitochondria. Annu Rev Cell Biol, 1988. 4: p. 289-333.
2. Garesse, R. and C.G. Vallejo, Animal mitochondrial biogenesis and function: a regulatory cross-talk between two genomes. Gene, 2001. 263(1-2): p. 1-16. 3. McBride, H.M., M. Neuspiel, and S. Wasiak, Mitochondria: more than just a powerhouse. Curr Biol, 2006. 16(14): p. R551-60. 4. Pieczenik, S.R. and J. Neustadt, Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol, 2007. 83(1): p. 84-92. 5. Reddy, P.H., Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease. Brain Res, 2011. 1415: p. 136-48. 6. Sherer, T.B., R. Betarbet, and J.T. Greenamyre, Environment, mitochondria, and Parkinson's disease. Neuroscientist, 2002. 8(3): p. 192-7. 7. Carod-Artal, F.J., et al., [Mitochondrial DNA deletions in Kearns-Sayre syndrome]. Neurologia, 2006. 21(7): p. 357-64. 8. Powers, S.K., et al., Mitochondrial signaling contributes to disuse muscle atrophy. Am J Physiol Endocrinol Metab, 2012. 303(1): p. 6. 9. Pangare, M. and A. Makino, Mitochondrial function in vascular endothelial cell in diabetes. J Smooth Muscle Res, 2012. 48(1): p. 1-26. 10. Barbosa, I.A., et al., Mitochondrial remodeling in cancer metabolism and survival: potential for new therapies. Biochim Biophys Acta, 2012. 1826(1): p. 238-54. 11. Warburg, O., F. Wind, and E. Negelein, The Metabolism of Tumors in the Body. J Gen Physiol, 1927. 8(6): p. 519-30. 12. Busk, M., et al., Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer, 2008. 122(12): p. 2726-34. 13. Pedersen, P.L., Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the 'Warburg Effect', i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr, 2007. 39(3): p. 211-22. 14. Gatenby, R.A. and R.J. Gillies, Why do cancers have high aerobic glycolysis? Nat Rev Cancer, 2004. 4(11): p. 891-9. 15. Zhou, C., et al., Inflammation linking EMT and cancer stem cells. Oral Oncol, 2012. 48(11): p. 1068-75. 16. Birnbaum, M.J., H.C. Haspel, and O.M. Rosen, Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. Science, 1987. 235(4795): p. 1495-8. 17. Shim, H., et al., c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A, 1997. 94(13): p. 6658-63. 18. Osthus, R.C., et al., Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem, 2000. 275(29): p. 21797-800. 19. Semenza, G.L., Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 2003. 3(10): p. 721-32. 20. Elstrom, R.L., et al., Akt stimulates aerobic glycolysis in cancer cells. Cancer Res, 2004. 64(11): p. 3892-9. 21. Bensaad, K., et al., TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell, 2006. 126(1): p. 107-20. 22. Selak, M.A., et al., Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 2005. 7(1): p. 77-85. 23. Gottlieb, E. and I.P. Tomlinson, Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer, 2005. 5(11): p. 857-66. 24. Cuezva, J.M., et al., The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res, 2002. 62(22): p. 6674-81. 25. Isidoro, A., et al., Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem J, 2004. 378(Pt 1): p. 17-20. 26. Jiang, W.G., A. Douglas-Jones, and R.E. Mansel, Expression of peroxisome-proliferator activated receptor-gamma (PPARgamma) and the PPARgamma co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. Int J Cancer, 2003. 106(5): p. 752-7. 27. Yin, P.H., et al., Alteration of the copy number and deletion of mitochondrial DNA in human hepatocellular carcinoma. Br J Cancer, 2004. 90(12): p. 2390-6. 28. Brandon, M., P. Baldi, and D.C. Wallace, Mitochondrial mutations in cancer. Oncogene, 2006. 25(34): p. 4647-62. 29. Bonuccelli, G., et al., The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle, 2010. 9(10): p. 1960-71. 30. Liu, Z. and R.A. Butow, Mitochondrial retrograde signaling. Annu Rev Genet, 2006. 40: p. 159-85. 31. Amuthan, G., et al., Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion. EMBO J, 2001. 20(8): p. 1910-20. 32. Biswas, G., et al., A distinctive physiological role for IkappaBbeta in the propagation of mitochondrial respiratory stress signaling. J Biol Chem, 2008. 283(18): p. 12586-94. 33. Amuthan, G., et al., Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells. Oncogene, 2002. 21(51): p. 7839-49. 34. Chandel, N.S., et al., Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem, 2000. 275(33): p. 25130-8. 35. Liu, H., et al., Redox-dependent transcriptional regulation. Circ Res, 2005. 97(10): p. 967-74. 36. Weinberg, F., et al., Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A, 2010. 107(19): p. 8788-93. 37. Fan, W., et al., mtDNA lineage analysis of mouse L-cell lines reveals the accumulation of multiple mtDNA mutants and intermolecular recombination. Genes Dev, 2012. 26(4): p. 384-94. 38. Petros, J.A., et al., mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci U S A, 2005. 102(3): p. 719-24. 39. Ishikawa, K., et al., ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science, 2008. 320(5876): p. 661-4. 40. Bellizzi, D., et al., Global DNA methylation levels are modulated by mitochondrial DNA variants. Epigenomics, 2012. 4(1): p. 17-27. 41. Minocherhomji, S., T.O. Tollefsbol, and K.K. Singh, Mitochondrial regulation of epigenetics and its role in human diseases. Epigenetics, 2012. 7(4): p. 326-34. 42. Fraga, M.F., et al., Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet, 2005. 37(4): p. 391-400. 43. Henderson, B.W. and T.J. Dougherty, How does photodynamic therapy work? Photochem Photobiol, 1992. 55(1): p. 145-57. 44. Van Hillegersberg, R., et al., Selective accumulation of endogenously produced porphyrins in a liver metastasis model in rats. Gastroenterology, 1992. 103(2): p. 647-51. 45. Svanberg, K., et al., Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation. Br J Dermatol, 1994. 130(6): p. 743-51. 46. Tsai, J.C., et al., Reorganization of cytoskeleton induced by 5-aminolevulinic acid-mediated photodynamic therapy and its correlation with mitochondrial dysfunction. Lasers Surg Med, 2005. 36(5): p. 398-408. 47. Tsai, T., et al., ALA-PDT results in phenotypic changes and decreased cellular invasion in surviving cancer cells. Lasers Surg Med, 2009. 41(4): p. 305-15. 48. Chiang, P.C., et al., Chloride intracellular channel 4 involves in the reduced invasiveness of cancer cells treated by photodynamic therapy. Lasers Surg Med, 2013. 45(1): p. 38-47. 49. Kobayashi, S., et al., Human PEG1/MEST, an imprinted gene on chromosome 7. Hum Mol Genet, 1997. 6(5): p. 781-6. 50. Pedersen, I.S., et al., Promoter switch: a novel mechanism causing biallelic PEG1/MEST expression in invasive breast cancer. Hum Mol Genet, 2002. 11(12): p. 1449-53. 51. Nakanishi, H., et al., Loss of imprinting of PEG1/MEST in lung cancer cell lines. Oncol Rep, 2004. 12(6): p. 1273-8. 52. Pedersen, I.S., et al., Frequent loss of imprinting of PEG1/MEST in invasive breast cancer. Cancer Res, 1999. 59(21): p. 5449-51. 53. Chang, C.C., et al., A novel carbazole derivative, BMVC: a potential antitumor agent and fluorescence marker of cancer cells. Chem Biodivers, 2004. 1(9): p. 1377-84. 54. Huang, F.C., et al., G-quadruplex stabilizer 3,6-bis(1-methyl-4-vinylpyridinium)carbazole diiodide induces accelerated senescence and inhibits tumorigenic properties in cancer cells. Mol Cancer Res, 2008. 6(6): p. 955-64. 55. Chu, J.F., et al., A Novel Method for Screening G-quadruplex Stabilizers to Human Telomeres. Jnl Chinese Chemical Soc, 2011. 58(3): p. 5. 56. 康繼之, BMVC 相關小分子於癌症的研究:癌症檢測與光動力治療, in 化學 研究所博士論文 2010, 國立清華大學. 57. Tarrago-Litvak, L., et al., The inhibition of mitochondrial DNA polymerase gamma from animal cells by intercalating drugs. Nucleic Acids Res, 1978. 5(6): p. 2197-210. 58. Amiri, M. and P.J. Hollenbeck, Mitochondrial biogenesis in the axons of vertebrate peripheral neurons. Dev Neurobiol, 2008. 68(11): p. 1348-61. 59. Chance, B., G.R. Williams, and G. Hollunger, Inhibition of electron and energy transfer in mitochondria. I. Effects of Amytal, thiopental, rotenone, progesterone, and methylene glycol. J Biol Chem, 1963. 238: p. 418-31. 60. Bryla, J., Z. Kaniuga, and E.C. Slater, Studies on the mechanism of inhibitionof the mitochondrial electron transport by antimycin. II. Antimycin as an allosteric inhibitor. Biochim Biophys Acta, 1969. 189(3): p. 317-26. 61. Hanstein, W.G., Uncoupling of oxidative phosphorylation. Biochim Biophys Acta, 1976. 456(2): p. 129-48. 62. Murphy, M.P., Targeting lipophilic cations to mitochondria. Biochim Biophys Acta, 2008. 1777(7-8): p. 1028-31. 63. Nunnari, J. and A. Suomalainen, Mitochondria: in sickness and in health. Cell, 2012. 148(6): p. 1145-59. 64. Singh, K.K., et al., Mitochondrial DNA determines the cellular response to cancer therapeutic agents. Oncogene, 1999. 18(48): p. 6641-6. 65. Lo, S., et al., Assessment of the significance of mitochondrial DNA damage by chemotherapeutic agents. Int J Oncol, 2005. 27(2): p. 337-44. 66. Ayalon, N., et al., Mitochondrial encoded NADH dehydrogenase 5 (MT-ND5) gene point mutation presents as late onset cardiomyopathy. Int J Cardiol, 2013. 67. Ishikawa, K., et al., Regulation of metastasis; mitochondrial DNA mutations have appeared on stage. J Bioenerg Biomembr, 2012. 44(6): p. 639-44. 68. Mkaouar-Rebai, E., et al., Screening of mitochondrial mutations in Tunisian patients with mitochondrial disorders: An overview study. Mitochondrial DNA, 2013. 24(3): p. 163-78. 69. Alfadda, A.A. and R.M. Sallam, Reactive oxygen species in health and disease. J Biomed Biotechnol, 2012. 2012: p. 936486. 70. Ding, W.X. and X.M. Yin, Mitophagy: mechanisms, pathophysiological roles, and analysis. Biol Chem, 2012. 393(7): p. 547-64. 71. Youle, R.J. and A.M. van der Bliek, Mitochondrial fission, fusion, and stress. Science, 2012. 337(6098): p. 1062-5. 72. Samocha-Bonet, D., et al., Overfeeding reduces insulin sensitivity and increases oxidative stress, without altering markers of mitochondrial content and function in humans. PLoS One, 2012. 7(5): p. e36320. 73. He, X., et al., Suppression of mitochondrial complex I influences cell metastatic properties. PLoS One, 2013. 8(4): p. e61677. 74. Chen, E.I., Mitochondrial dysfunction and cancer metastasis. J Bioenerg Biomembr, 2012. 44(6): p. 619-22. 75. Shu, M., et al., Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells. Mol Cancer, 2011. 10: p. 59. 76. Yan, Z., et al., Identification of hsa-miR-335 as a prognostic signature in gastric cancer. PLoS One, 2012. 7(7): p. e40037. 77. Lynch, J., et al., MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-beta signalling pathway. Carcinogenesis, 2012. 33(5): p. 976-85. 78. Tavazoie, S.F., et al., Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 2008. 451(7175): p. 147-52. 79. Scarola, M., et al., miR-335 directly targets Rb1 (pRb/p105) in a proximal connection to p53-dependent stress response. Cancer Res, 2010. 70(17): p. 6925-33. 80. Tome, M., et al., miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells. Cell Death Differ, 2011. 18(6): p. 985-95. 81. Ronchetti, D., et al., An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Med Genomics, 2008. 1: p. 37. 82. Dolmans, D.E., D. Fukumura, and R.K. Jain, Photodynamic therapy for cancer. Nat Rev Cancer, 2003. 3(5): p. 380-7. 83. Poblete-Gutierrez, P., et al., The porphyrias: clinical presentation, diagnosis and treatment. Eur J Dermatol, 2006. 16(3): p. 230-40. 84. Venkatesh, S., et al., Multitasking in the mitochondrion by the ATP-dependent Lon protease. Biochim Biophys Acta, 2012. 1823(1): p. 56-66. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61798 | - |
dc.description.abstract | 粒線體是細胞中最主要的能量提供者,同時它也扮演著傳遞訊息以及調控細 胞的生長分化和死亡的重要角色。在許多疾病,諸如神經退化性疾病、肌無力、 以及癌症中,也發現病患細胞中的粒線體和一般正常的粒線體有所不同,而許多 研究也發現這些功能異常的粒線體會造成細胞核內基因表現的改變,此現象稱作 「回溯訊息」(retrograde signal)。由本實驗室先前的研究發現,使用 ALA Photodynamic Therapy(ALA-PDT)反覆處理所建立的粒線體功能異常 (mitochondrial dysfunction)細胞株中,癌細胞的移動能力顯著地被抑制,並伴隨 著核內基因表現的改變。先前已有研究發現 BMVC-12C 這種小分子化合物可以專 一地累積在癌細胞粒線體中,所以本研究想探討 BMVC-12C 能否成為一個使粒線 體功能異常的工具,並觀察其後續生物效應是否和本實驗室先前發現的結果相同。 首先,在細胞毒性測試的實驗中,我們發現 BMVC-12C 會抑制癌細胞的生長複製, 但在低濃度的情況下並不會造成其死亡。為研究 BMVC-12C 是否會影響粒線體的 功能,我們做了一系列對粒線體功能的分析。結果發現伴隨活性氧化物(Reactive Oxygen Species,ROS)的產生,粒線體確實有功能異常的情況,進一步的研究顯 示造成粒線體功能異常的原因則是來自於 BMVC-12C 抑制了粒線體 DNA(mtDNA) 的複製。接著,在細胞移動能力的實驗中我們同樣觀察到 BMVC-12C 處理的細胞 其移動能力顯著下降。最後,我們將 BMVC-12C 處理過的細胞進行基因表現的分 析,發現 PEG-1/MEST 基因的表現量在藥物處理後顯著的下降,呼應先前細胞移 動能力的結果,且亦符合之前在 ALA-PDT 中所觀察到的結果。 | zh_TW |
dc.description.abstract | Except for providing ATP, mitochondria also regulate cell growth, death, and differentiation. Many studies showed that mitochondrial dysfunction involved in many diseases, like neurodegenerative disease, myopathy, and cancer. It has been shown that mitochondrial dysfunction might affect the expression profile of nuclear genes via the so called “mitochondrial retrograde signaling”. Previously, our lab found that the migration and invasion ability of the PDT-derived variants was significantly decreased. Meanwhile, a small molecule named “BMVC-12C” has been found to localize in mitochondria. In this study, we would like to examine whether BMVC-12C can induce mitochondrial dysfunction and further investigate the following biological consequences. We found out that BMVC-12C can inhibit cell growth at low concentration. Further studies showed that BMVC-12C treatment led to mitochondrial dysfunction and the production of reactive oxygen species (ROS) was also observed. Meanwhile, we found that the BMVC-12C could inhibit the replication of mitochondrial DNA (mtDNA). Finally, we showed that BMVC-12C treatment can reduce cell migration ability and the expression level of PEG-1/MEST gene | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T13:13:37Z (GMT). No. of bitstreams: 1 ntu-102-R00b22032-1.pdf: 11284887 bytes, checksum: d6d1db31c4a3bf75eb32cb7edc35fb38 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 摘要 ..........................................................................................................I
Abstract .................................................................................................................II 目錄 ................................................................................................................III 第一章 緒論 1.2 粒線體功能異常(Mitochondrial dysfunction)......................................... 1 1.3 粒線體功能異常與癌細胞(Mitochondrial dysfunction and cancer) ...........2 1.4 粒線體回溯訊息調控(Retrograde signaling)............................................3 1.5 五-氨基酮戊酸光動力治療(5-Aminolevulinic acid mediated photodynamic therapy,ALA-PDT)..............................................................5 1.5.1 光動力治療(photodynamic therapy,PDT)............................................5 1.5.2 五-氨基酮戊酸(5-Aminolevulinic acid,ALA)........................................5 1.5.3 利用 ALA-PDT 引發的粒線體功能異常對粒線體回溯訊息調控進行 研究.............................................................................................................6 1.6 PEG-1/MEST 基因與細胞移動能力的關聯................................................6 1.7 BMVC ................................................................................................................7 1.7.1 端粒酶抑制劑-BMVC .........................................................................7 1.7.2 BMVC-12C..........................................................................................................7 1.8 研究動機與目的....................................................................................8 第二章 材料與方法 2.1 藥品與儀器.........................................................................................10 2.1.1 藥品...............................................................................................10 2.1.2 儀器...............................................................................................12 2.2 細胞培養 ..............................................................................................................12 2.2.1 細胞繼代........................................................................................12 2.2.2 細胞冷凍與解凍 ..............................................................................13 2.2.3 細胞計數.........................................................................................13 2.3 BMVC-12C 配製 ...............................................................................13 2.4 細胞群落形成之分析(Colony formation assay) .....................................14 2.5 細胞存活率分析-粒線體去氫酶活性分析(MTT assay) ..............................14 2.6 粒線體含量分析:檸檬酸合成酶(Citrate synthase)活性分析.......................14 2.7 粒線體功能分析..................................................................................15 2.8 粒線體 DNA 複製分析.........................................................................15 2.9 活性氧化物(Reactive Oxygen Species,ROS)的產生................................16 2.10 細胞移動能力測試(Transwell Migration Assay) ..................................16 2.11 Reverse Transcription-Polymerase Chain Reaction(RT-PCR) ...........16 2.11.1 RNA 萃取(RNA extraction) ...........................................................16 2.11.2 反轉錄作用(Reverse transcription,RT)............................................16 2.11.3 聚合酶鏈鎖反應(Polymerase chain reaction,PCR)............................16 2.11.4 洋菜膠體電泳分析(Agarose electrophoresis)...................................17 第三章 結果 3.1 BMVC-12C 對細胞生長的影響 ............................................................19 3.1.1 不同濃度的 BMVC-12C 對細胞的影響 ...............................................19 3.1.2 不同濃度的 BMVC-12C 對細胞生長及複製的影響................................19 3.2 BMVC-12C 對粒線體功能影響之探討 ...................................................20 3.2.1 粒線體功能分析 ..............................................................................20 3.2.2 細胞內粒線體含量測試(Citrate Synthase activity test)........................21 3.2.3 活性氧化物(Reactive Oxygen Species,ROS)的產生.............................22 3.2.4 粒線體 DNA(mtDNA)複製受影響 ..................................................... 23 3.3 BMVC-12C 所導致之粒線體功能異常造成細胞移動能力及 PEG-1/MEST 基因表現量改變 ..............................................................................................24 3.3.1 BMVC-12C 處理後細胞移動能力分析 ................................................24 3.3.2 BMVC-12C 處理後細胞 PEG-1/MEST 基因表現量分析........................24 3.4 以 BMVC 處理和 BMVC-12C 處理對 PEG-1/MEST 基因表現量做比較......25 第四章 討論 4.1 BMVC-12C 作用於粒線體 DNA 機制探討..............................................26 4.2 BMVC-12C 影響細胞粒線體功能及細胞生長探討 ...................................27 4.2.1 BMVC-12C 影響粒線體功能 ............................................................27 4.2.2 BMVC-12C 影響細胞生長 ................................................................29 4.3 粒線體功能異常影響細胞移動能力以及 PEG-1/MEST 基因表現量探討.......30 4.4 細胞移動能力和 PEG-1/MEST 基因的關聯.............................................31 第五章 結論 5.1 BMVC-12C 能影響線體 DNA 的複製....................................................33 5.2 BMVC-12C 影響粒線體 DNA 複製會導致粒線體功能異常........................33 5.3 BMVC-12C 引發的粒線體功能異常使細胞移動能力下降 .........................33 5.4 BMVC-12C 引發的粒線體功能異常使 PEG-1/MEST 基因表現量改變........34 結果圖 ....................................................................................................51 附圖........................................................................................................51 參考文獻...................................................56 | |
dc.language.iso | zh-TW | |
dc.title | BMVC衍生物誘發粒線體功能異常對細胞移動能力及其相關調控基因的探討 | zh_TW |
dc.title | Investigate the Effect of Mitochondrial Dysfunction Induced by a BMVC Derivative on Cell Migration and Related Genes Expression | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蔡翠敏(Tsui-Min Tsai),黃慶璨(Ching-Tsan Huang),張大釗(Ta-Chau Chang) | |
dc.subject.keyword | 粒線體功能異常,ALA-PDT,BMVC-12C,PEG-1/MEST, | zh_TW |
dc.subject.keyword | mitochondrial dysfunction,ALA-PDT,BMVC-12C,PEG-1/MEST, | en |
dc.relation.page | 62 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2013-07-30 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科技學系 | zh_TW |
顯示於系所單位: | 生化科技學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 11.02 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。